Alan Tudyk says he was cut out of “I, Robot” press after 'testing higher than Will Smith' with audiences US consumer prices ...

If Novo Nordisk A/S’s wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer’s disease, Biogen Inc.’s Chief Executive Officer Chris Viehbacher doesn’t see it as a ...

Currently, the NHS offers a range of services to help people manage their obesity, including prescription weight loss medication like Mounjaro and the NHS Digital Weight Management Programme. This is ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could ...

Eli Lilly specializes in obesity and diabetes treatments, among other areas. It's reasonable to expect a lot more growth from ...

The UK government will contribute up to £50 million of new investment into the scheme, with Lilly contributing up to £35 ...

In a recent interview with Men’s Health, Alden Ehrenreich revealed that when the discussion about his role in Weapons started ...

For $1.3 billion in aggregate—including upfront and milestone payments—Bayer will get exclusive global access to Kumquat ...

A daily dose of blarcamesine restored autophagy among patients with early Alzheimer’s disease, with improved outcomes through 192 weeks, according to an abstract presented at the Alzheimer’s ...

Over the past five years, Eli Lilly stock has risen roughly 320% as of market close Aug. 11. Meanwhile, the company has ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

The obesity market still only has two clear leaders with approved GLP-1 medications, and frontrunners Eli Lilly and Novo ...